{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T21:09:49Z","timestamp":1778620189697,"version":"3.51.4"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T00:00:00Z","timestamp":1652313600000},"content-version":"vor","delay-in-days":72,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017317","name":"Catholic Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017317","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004896","name":"Eisai Incorporated","doi-asserted-by":"publisher","award":["332"],"award-info":[{"award-number":["332"]}],"id":[{"id":"10.13039\/501100004896","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.yebeh.2021.108528","type":"journal-article","created":{"date-parts":[[2022,1,22]],"date-time":"2022-01-22T06:52:11Z","timestamp":1642834331000},"page":"108528","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Sustained seizure freedom with adjunctive perampanel in patients with convulsive seizures: Post hoc analysis of open-label extension studies 307 and 332"],"prefix":"10.1016","volume":"128","author":[{"given":"Trevor","family":"Resnick","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Patten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leock Y.","family":"Ngo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manoj","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2021.108528_b0005","unstructured":"World Health Organization (WHO). Epilepsy Key Facts, https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/epilepsy; 2019 [June 30, 2021]."},{"issue":"5","key":"10.1016\/j.yebeh.2021.108528_b0010","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM200002033420503","article-title":"Early identification of refractory epilepsy","volume":"342","author":"Kwan","year":"2000","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.yebeh.2021.108528_b0015","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1528-1167.2011.03354.x","article-title":"Do antiepileptic drugs or generalized tonic-clonic seizure frequency increase SUDEP risk? A combined analysis","volume":"53","author":"Hesdorffer","year":"2012","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.yebeh.2021.108528_b0020","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/j.1528-1167.2010.02952.x","article-title":"Combined analysis of risk factors for SUDEP","volume":"52","author":"Hesdorffer","year":"2011","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.yebeh.2021.108528_b0025","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.seizure.2011.10.009","article-title":"Physical injuries in patients with epilepsy and their associated risk factors","volume":"21","author":"Asadi-Pooya","year":"2012","journal-title":"Seizure"},{"issue":"10","key":"10.1016\/j.yebeh.2021.108528_b0030","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1517\/14656566.2014.915029","article-title":"Pharmacotherapy for tonic-clonic seizures","volume":"15","author":"Rheims","year":"2014","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.yebeh.2021.108528_b0035","unstructured":"Food and Drug Administration (FDA). FYCOMPA\u00ae Prescribing Information, https:\/\/www.fycompa.com\/-\/media\/Files\/Fycompa\/Fycompa_Prescribing_Information.pdf; February 2021 [July 1, 2021]."},{"issue":"6","key":"10.1016\/j.yebeh.2021.108528_b0040","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1212\/WNL.0b013e3182635735","article-title":"Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304","volume":"79","author":"French","year":"2012","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.yebeh.2021.108528_b0045","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1528-1167.2012.03638.x","article-title":"Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305","volume":"54","author":"French","year":"2013","journal-title":"Epilepsia"},{"issue":"18","key":"10.1016\/j.yebeh.2021.108528_b0050","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1212\/WNL.0b013e318254473a","article-title":"Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures","volume":"78","author":"Krauss","year":"2012","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.yebeh.2021.108528_b0055","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1212\/WNL.0000000000001930","article-title":"Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy: a randomized trial","volume":"85","author":"French","year":"2015","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.yebeh.2021.108528_b0060","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/epi.14044","article-title":"Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: study 307","volume":"59","author":"Krauss","year":"2018","journal-title":"Epilepsia"},{"issue":"8","key":"10.1016\/j.yebeh.2021.108528_b0065","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1111\/epi.12212","article-title":"Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies","volume":"54","author":"Steinhoff","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.108528_b0070","series-title":"Treatment of Epilepsy: Principles and Practice","author":"Wyllie","year":"2011"},{"issue":"5","key":"10.1016\/j.yebeh.2021.108528_b0075","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1093\/brain\/awl047","article-title":"Absence and myoclonic status epilepticus precipitated by antiepileptic drugs in idiopathic generalized epilepsy","volume":"129","author":"Thomas","year":"2006","journal-title":"Brain"},{"issue":"11","key":"10.1016\/j.yebeh.2021.108528_b0080","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.33.11.1487","article-title":"Myoclonic, atonic, and absence seizures following institution of carbamazepine therapy in children","volume":"33","author":"Shields","year":"1983","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.yebeh.2021.108528_b0085","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1111\/j.1528-1167.2007.01210.x","article-title":"Aggravation of seizures and\/or EEG features in children treated with oxcarbazepine monotherapy","volume":"48","author":"Vendrame","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.108528_b0090","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.seizure.2020.06.011","article-title":"Adjunctive perampanel and myoclonic and absence seizures: Post hoc analysis of data from study 332 in patients with idiopathic generalized epilepsy","volume":"80","author":"Brandt","year":"2020","journal-title":"Seizure"},{"issue":"2","key":"10.1016\/j.yebeh.2021.108528_b0095","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/epi.16428","article-title":"Efficacy and safety of adjunctive perampanel 4 mg\/d for the treatment of focal seizures: A pooled post hoc analysis of four randomized, double-blind, phase III studies","volume":"61","author":"Steinhoff","year":"2020","journal-title":"Epilepsia"},{"issue":"8","key":"10.1016\/j.yebeh.2021.108528_b0100","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1111\/epi.12240","article-title":"Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures","volume":"54","author":"Gidal","year":"2013","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.yebeh.2021.108528_b0105","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/ane.12874","article-title":"Pharmacokinetic\/pharmacodynamic analysis of adjunctive perampanel in subjects with partial-onset seizures","volume":"137","author":"Takenaka","year":"2018","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2021.108528_b0110","unstructured":"European Medicines Agency (EMA). FYCOMPA\u00ae Annex I: Summary of Product Characteristics, https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/fycompa-epar-product-information_en.pdf; January 2021 [November 4, 2021]."}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505021007897?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505021007897?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:08:20Z","timestamp":1778616500000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505021007897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":22,"alternative-id":["S1525505021007897"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2021.108528","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sustained seizure freedom with adjunctive perampanel in patients with convulsive seizures: Post hoc analysis of open-label extension studies 307 and 332","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2021.108528","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108528"}}